Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/186085
Title: | The Hidden Side of Complement Regulator C4BP: Dissection and Evaluation of Its Immunomodulatory Activity |
Author: | Serrano, Inmaculada Luque, Ana Mitjavila Villeró, Francesca Blom, Anna M. Rodríguez de Córdoba, Santiago Vega Fernández, Maria Cristina Torras Ambròs, Joan Aran Perramon, Josep M. |
Keywords: | Immunoregulació Lupus Immunoregulation Lupus |
Issue Date: | 25-Apr-2022 |
Publisher: | Frontiers Media |
Abstract: | C4b-binding protein (C4BP) is a well-known regulator of the complement system that holds additional and important activities unrelated to complement inhibition. Recently, we have described a novel immunomodulatory activity in the minor C4BP(beta-) isoform directly acting over inflammatory phagocytes. Here we show that incorporation of the beta-chain to the C4BP alpha-chain oligomer interferes with this immunomodulatory activity of C4BP. Moreover, an oligomeric form including only the complement control protein 6 (CCP6) domain of the C4BP alpha-chain (PRP6-HO7) is sufficient to reprogram monocyte-derived DCs (Mo-DCs) from a pro-inflammatory and immunogenic phenotype to an anti-inflammatory and tolerogenic state. PRP6-HO7 lacks complement regulatory activity but retains full immunomodulatory activity over inflammatory Mo-DCs induced by TLRs, characterized by downregulation of relevant surface markers such as CD83, HLA-DR, co-stimulatory molecules such as CD86, CD80 and CD40, and pro-inflammatory cytokines such as IL-12 and TNF-alpha. Furthermore, PRP6-HO7-treated Mo-DCs shows increased endocytosis, significantly reduced CCR7 expression and CCL21-mediated chemotaxis, and prevents T cell alloproliferation. Finally, PRP6-HO7 shows also full immunomodulatory activity over Mo-DCs isolated from lupus nephritis patients with active disease, even without further pro-inflammatory stimulation. Therefore PRP6-HO7, retaining the immunomodulatory activity of C4BP(beta-) and lacking its complement regulatory activity, might represent a promising and novel alternative to treat autoimmune diseases. |
Note: | Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2022.883743 |
It is part of: | Frontiers in Immunology, 2022, vol. 13 |
URI: | http://hdl.handle.net/2445/186085 |
Related resource: | https://doi.org/10.3389/fimmu.2022.883743 |
ISSN: | 1664-3224 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fimmu-13-883743.pdf | 5.96 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License